Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 422

1.

VHA Multiple Sclerosis Surveillance Registry and its similarities to other contemporary multiple sclerosis cohorts.

Culpepper WJ, Wallin MT, Magder LS, Perencevich E, Royal W, Bradham DD, Cutter G, Bever CT.

J Rehabil Res Dev. 2015;52(3). doi: 10.1682/JRRD.2014.07.0172.

PMID:
26220064
2.

Divergent responses of Atlantic coastal and oceanic Synechococcus to iron limitation.

Mackey KR, Post AF, McIlvin MR, Cutter GA, John SG, Saito MA.

Proc Natl Acad Sci U S A. 2015 Jul 27. pii: 201509448. [Epub ahead of print]

3.

To treat or not to treat, that really is not the question.

Wang G, Cutter GR.

Neurol Clin Pract. 2015 Jun;5(3):253-258. No abstract available.

PMID:
26124983
4.

Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study.

Govindarajan KA, Datta S, Hasan KM, Choi S, Rahbar MH, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston, The CombiRx Investigators Group.

Hum Brain Mapp. 2015 Jun 19. doi: 10.1002/hbm.22875. [Epub ahead of print]

PMID:
26096844
5.

Pooling Morphometric Estimates: A Statistical Equivalence Approach.

Pardoe HR, Cutter GR, Alter R, Hiess RK, Semmelroch M, Parker D, Farquharson S, Jackson GD, Kuzniecky R.

J Neuroimaging. 2015 Jun 21. doi: 10.1111/jon.12265. [Epub ahead of print]

PMID:
26094850
6.

Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov.

Lebensburger JD, Hilliard LM, Pair LE, Oster R, Howard TH, Cutter GR.

Clin Trials. 2015 Jun 17. pii: 1740774515590811. [Epub ahead of print]

PMID:
26085544
7.

Risk tolerance to MS therapies: Survey results from the NARCOMS registry.

Fox RJ, Salter A, Alster JM, Dawson NV, Kattan MW, Miller D, Ramesh S, Tyry T, Wells BW, Cutter G.

Mult Scler Relat Disord. 2015 May;4(3):241-9. doi: 10.1016/j.msard.2015.03.003. Epub 2015 Mar 26.

PMID:
26008941
8.

Impact of multiple sclerosis relapse: The NARCOMS participant perspective.

Nickerson M, Cofield SS, Tyry T, Salter AR, Cutter GR, Marrie RA.

Mult Scler Relat Disord. 2015 May;4(3):234-40. doi: 10.1016/j.msard.2015.03.005. Epub 2015 Mar 27.

9.

Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.

Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S.

Mult Scler Relat Disord. 2014 Nov;3(6):705-11. doi: 10.1016/j.msard.2014.08.005. Epub 2014 Sep 6.

10.

Bifactor structure of clinical disability in relapsing multiple sclerosis.

Chamot E, Kister I, Cutter GR.

Mult Scler Relat Disord. 2014 Mar;3(2):176-85. doi: 10.1016/j.msard.2013.06.005. Epub 2013 Jul 12.

PMID:
25878005
11.

Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab.

Rinker JR 2nd, Salter AR, Cutter GR.

Mult Scler Relat Disord. 2014 Jul;3(4):505-12. doi: 10.1016/j.msard.2014.04.001. Epub 2014 Apr 8.

PMID:
25877063
12.

Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S.

Kaufman DW, Reshef S, Golub HL, Peucker M, Corwin MJ, Goodin DS, Knappertz V, Pleimes D, Cutter G.

Mult Scler Relat Disord. 2014 May;3(3):364-71. doi: 10.1016/j.msard.2013.12.003. Epub 2013 Dec 25.

PMID:
25876474
13.

Multiple sclerosis drugs: how much bang for the buck?

Stüve O, Cutter GR.

Lancet Neurol. 2015 May;14(5):460-1. doi: 10.1016/S1474-4422(15)00016-2. Epub 2015 Apr 1. No abstract available.

PMID:
25841666
14.

Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.

Datta S, Staewen TD, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston; CombiRx Investigators Group.

Mult Scler Relat Disord. 2015 Mar;4(2):124-36. doi: 10.1016/j.msard.2015.01.004. Epub 2015 Jan 17.

PMID:
25787188
15.

Factors associated with early childhood caries incidence among high caries-risk children.

Ghazal T, Levy SM, Childers NK, Broffitt B, Cutter GR, Wiener HW, Kempf MC, Warren J, Cavanaugh JE.

Community Dent Oral Epidemiol. 2015 Aug;43(4):366-74. doi: 10.1111/cdoe.12161. Epub 2015 Mar 16.

PMID:
25777317
16.

The promise of futility trials in neurological diseases.

Koch MW, Korngut L, Patry DG, Agha-Khani Y, White C, Sarna JR, Yeung M, Yong VW, Heng DY, Cutter G, Metz L.

Nat Rev Neurol. 2015 May;11(5):300-5. doi: 10.1038/nrneurol.2015.34. Epub 2015 Mar 17. Review.

PMID:
25776824
17.

Translation of a Ski School Sun Safety Program to North American Ski and Snowboard Schools.

Walkosz BJ, Buller DB, Andersen PA, Scott MD, Liu X, Cutter GR, Dignan MB.

Health Promot Pract. 2015 Jul;16(4):560-70. doi: 10.1177/1524839915577081. Epub 2015 Mar 11.

PMID:
25761916
18.

Differences in Alzheimer disease clinical trial outcomes based on age of the participants.

Schneider LS, Kennedy RE, Wang G, Cutter GR.

Neurology. 2015 Mar 17;84(11):1121-7. doi: 10.1212/WNL.0000000000001376. Epub 2015 Feb 13.

PMID:
25681452
19.

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.

Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S, Cutter G, Reider N.

Mult Scler. 2015 Mar;21(3):263-81. doi: 10.1177/1352458514564491. Epub 2015 Jan 26.

20.

Capacity of patients with brain metastases to make treatment decisions.

Triebel KL, Gerstenecker A, Meneses K, Fiveash JB, Meyers CA, Cutter G, Marson DC, Martin RC, Eakin A, Watts O, Nabors LB.

Psychooncology. 2015 Jan 23. doi: 10.1002/pon.3753. [Epub ahead of print]

PMID:
25613039
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk